Stefan Bissinger

Company: iOmx Therapeutics

Job title: Head of Preclinical Pharmacology & Biomarker Development

Seminars:

Investigating Safety & Efficacy of IOMX-0675 a Cross-Specific Antibody Unleashing Tumor Microenvironment Repolarisation & Activation by Targeting LILRB1/2 in Innovative In Vitro, Ex Vivo & Humanised In Vivo Cancer Models 2:00 pm

Selection and characterisation of the best-in class candidate IOMX-0675 using in vitro primary immune cells assays and ex vivo whole blood systems Translating myeloid – T cell biology into pharmacodynamic activity in advanced myeloid engrafted humanised mouse modelsRead more

day: Conference Day 1